A detailed history of Daiwa Securities Group Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 447 shares of APLS stock, worth $12,542. This represents 0.0% of its overall portfolio holdings.

Number of Shares
447
Previous 447 -0.0%
Holding current value
$12,542
Previous $17,000 23.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
$55.39 - $72.47 $2,104 - $2,753
-38 Reduced 7.84%
447 $26,000
Q4 2023

Jan 31, 2024

BUY
$37.14 - $64.82 $2,451 - $4,278
66 Added 15.75%
485 $29,000
Q2 2023

Jul 31, 2023

SELL
$76.68 - $93.31 $1,993 - $2,426
-26 Reduced 5.84%
419 $38,000
Q4 2022

Feb 06, 2023

BUY
$43.24 - $61.04 $2,075 - $2,929
48 Added 12.09%
445 $23,000
Q2 2022

Aug 09, 2022

BUY
$35.07 - $59.21 $3,471 - $5,861
99 Added 33.22%
397 $18,000
Q3 2021

Nov 05, 2021

BUY
$31.4 - $69.84 $4,364 - $9,707
139 Added 87.42%
298 $10,000
Q1 2021

May 03, 2021

BUY
$40.8 - $57.39 $693 - $975
17 Added 11.97%
159 $7,000
Q4 2020

Feb 04, 2021

SELL
$30.79 - $57.2 $8,528 - $15,844
-277 Reduced 66.11%
142 $8,000
Q1 2020

May 14, 2020

BUY
$17.91 - $44.33 $1,038 - $2,571
58 Added 16.07%
419 $11,000
Q4 2019

Jan 31, 2020

SELL
$22.1 - $30.8 $817 - $1,139
-37 Reduced 9.3%
361 $11,000
Q2 2019

Jul 24, 2019

BUY
$18.0 - $25.34 $720 - $1,013
40 Added 11.17%
398 $10,000
Q1 2019

Apr 26, 2019

SELL
$12.81 - $19.82 $1,819 - $2,814
-142 Reduced 28.4%
358 $7,000
Q4 2018

Feb 05, 2019

BUY
$11.47 - $18.71 $5,735 - $9,355
500 New
500 $7,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.08B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.